The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Characterization of POLE-mutated (POLE+) urothelial carcinoma of the bladder and urinary tract (UC).
 
MinYuen Teo
No Relationships to Disclose
 
Hikmat Al-Ahmadie
No Relationships to Disclose
 
Eugene K. Cha
No Relationships to Disclose
 
Guido Dalbagni
No Relationships to Disclose
 
Bernard H. Bochner
No Relationships to Disclose
 
David B. Solit
Honoraria - Loxo; Pfizer
Consulting or Advisory Role - Loxo; Pfizer
 
Michael F. Berger
Consulting or Advisory Role - Cancer Genetics; Loxo; Sequenom
 
Barry S. Taylor
No Relationships to Disclose
 
Dean F. Bajorin
Honoraria - Merck Sharp & Dohme
Consulting or Advisory Role - Bristol-Myers Squibb; Eisai; Fidia Farmaceutici S. p. A.; Genentech; Lilly; Lilly; Merck; Novartis; Roche; Roche/Genentech; Urogen pharma
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); dendreon (Inst); Genentech/Roche (Inst); Merck (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Lilly; Merck; Roche/Genentech
 
Gopa Iyer
No Relationships to Disclose
 
Jonathan E. Rosenberg
Stock and Other Ownership Interests - Illumina; Merck
Honoraria - UpToDate
Consulting or Advisory Role - Boehringer Ingelheim; Bristol-Myers Squibb; Dendreon; Janssen Oncology; Johnson & Johnson; Lilly; Merck; Oncogenex; Onyx
Research Funding - Agensys; Genentech; Mirati Therapeutics; Oncogenex
Patents, Royalties, Other Intellectual Property - ERCC2 predicting cisplatin sensitivity
Travel, Accommodations, Expenses - Genentech/Roche